Rosetta Receives NY State Clearance for Second-Gen Test for Cancer of Unknown Primary | GenomeWeb

Rosetta Genomics said this week that the New York State Department of Health has approved the company's miRview Mets 2 microRNA diagnostic, which is used to detect the source of cancers of unknown primary origin.

New York is the only state that requires an independent regulatory review for laboratory-developed tests, Rosetta noted.

With the approval, Rosetta said it can now market the test in all 50 US states.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.